-
公开(公告)号：US20240343710A1
公开(公告)日：2024-10-17
申请号：US18583024
申请日：2024-02-21
Applicant: 1cBio, Inc.
Inventor： Jayakanth KANKANALA , Jeremy D. PETTIGREW , Son Minh PHAM
IPC: C07D401/14 , A61K31/439 , A61K31/444 , A61K31/501 , A61K31/5383 , A61P31/00 , C07D407/14 , C07D487/08 , C07D487/16 , C07D498/16
CPC classification number: C07D401/14 , A61K31/439 , A61K31/444 , A61K31/501 , A61K31/5383 , A61P31/00 , C07D407/14 , C07D487/08 , C07D487/16 , C07D498/16
Abstract: The present disclosure relates to compounds of Formula (I):
and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.-
2.发明公开公开(公告)号：US20240342171A1
公开(公告)日：2024-10-17
申请号：US18294472
申请日：2022-08-16
Applicant: Nanyang Technological University
Inventor： Gerhard GRÜBER , Roderick Wayland BATES , Priya RAGUNATHAN
IPC: A61K31/505 , A61K31/498 , A61K45/06 , A61P31/00
CPC classification number: A61K31/505 , A61K31/498 , A61K45/06 , A61P31/00
Abstract: Disclosed herein is the use of a compound of formula I, or a salt or a solvate thereof, in the treatment of a bacterial infection caused by Mycobacterium abscessus, where the compound of formula (I) has the following formula: I where: R1, Ra, R2, R3, X, Y, Z and R4 are as defined herein. Also disclosed herein are combination treatments using the compound of formula I and pharmaceutical formulations comprising said compound.
-
公开(公告)号：US12115184B2
公开(公告)日：2024-10-15
申请号：US17343471
申请日：2021-06-09
Applicant: AMORPHICAL LTD.
Inventor： Yosef Ben , Yigal Dov Blum , Hagay Moshe , Ben Ashkenazi
CPC classification number: A61K33/10 , A61K9/0019 , A61K9/0056 , A61K9/0073 , A61K9/10 , A61K9/143 , A61K47/24 , A61P31/00 , A61P35/00
Abstract: The present invention provides solid compositions of amorphous calcium carbonate (ACC) and a polyphosphate, bisphosphonate or pharmaceutical salts thereof as a stabilizer. Said stabilizers stabilizes the ACC and prevent crystallization to crystalline calcium carbonate (CCC) for a long period of time, even in an aqueous suspension. The invention further provides pharmaceutical composition comprising the solid ACC compositions as well their use in treating of certain diseases and conditions.
-
公开(公告)号：US12110320B2
公开(公告)日：2024-10-08
申请号：US17698645
申请日：2022-03-18
Inventor： Samuel Lai , M. Gregory Forest , Christine Henry , Timothy Wessler , Alexander Chen , Jennifer Schiller , Jay Newby
IPC: A61K39/04 , A61P31/00 , C07K16/08 , C07K16/10 , C07K16/12 , C07K16/44 , G01N33/543 , G01N33/557 , G01N33/569 , G01N33/68 , A61K38/00
CPC classification number: C07K16/1235 , A61P31/00 , C07K16/087 , C07K16/1045 , C07K16/44 , G01N33/54346 , G01N33/557 , G01N33/56983 , G01N33/6854 , A61K38/00 , C07K2317/41 , G01N2333/16 , G01N2333/4725
Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.
-
5.发明公开公开(公告)号：US20240285723A1
公开(公告)日：2024-08-29
申请号：US18573517
申请日：2022-06-22
Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor： Yankel GABET , Josef MOGRABI
IPC: A61K38/08 , A61K31/015 , A61K31/497 , A61K31/566 , A61K31/573 , A61P31/00 , A61P37/06
CPC classification number: A61K38/08 , A61K31/015 , A61K31/497 , A61K31/566 , A61K31/573 , A61P31/00 , A61P37/06
Abstract: Pharmaceutical compositions are provided, comprising at least one selective CB2 receptor agonist and at least one steroid. The provided compositions are effective in treating inflammation and/or pathogen related inflammation and associated complications thereof. Also provided are methods for treating a subject infected with a pathogen as well as inflammation, using said compositions.
-
Patent Agency Ranking
公开(公告)号：US20240269231A1
公开(公告)日：2024-08-15
申请号：US18616600
申请日：2024-03-26
Applicant: Ohio University
Inventor： John J. Kopchick , Vishwajeet Puri , Vishva Sharma , Reetobrata Basu
CPC classification number: A61K38/1761 , A61P31/00 , A61P35/00
Abstract: FSP27 compositions and methods for treating cancers are described.
-
公开(公告)号：US20240261197A1
公开(公告)日：2024-08-08
申请号：US18443435
申请日：2024-02-16
Applicant: SYMRISE AG
Inventor： Imke MEYER , Ravikumar PILLAI
Abstract: Suggested is an antimicrobial mixture comprising or consisting of
(a) at least one monocyclic sesquiterpene alcohol,
(b) at least one active selected from the group consisting of 4-hydroxyacetophenone, sorbitan caprylate, cocamidopropyl PG-dimonium chloride phosphate, tetrasodium glutamate diacetate, glyceryl caprylate and glyceryl caprate, and optionally
(c) at least one additional antimicrobial agent different from components (a) and (b).-
公开(公告)号：US20240189237A1
公开(公告)日：2024-06-13
申请号：US18285645
申请日：2021-04-07
Applicant: WATERSHED MEDICAL INC
IPC: A61K9/16 , A61K9/00 , A61K31/546 , A61K31/555 , A61P31/00
CPC classification number: A61K9/1676 , A61K9/0034 , A61K9/1617 , A61K9/1641 , A61K31/546 , A61K31/555 , A61P31/00
Abstract: The invention provides a formulation and method for the treatment of urinary system disorders, wherein the formulation comprises a controlled release drug delivery system for intravesicular administration to a patient. Controlled release microparticles in the formulation are comprised of a pharmacologically active agent and a controlled release carrier, where the microparticles are buoyant in urine. Microparticle buoyancy in urine ensures that the formulation continues to release the active agent into a patient's bladder throughout the duration of an extended drug delivery time period. Methods of treating urinary system disorders by intravesicular administration of the microparticle formulation to a subject are also provided, and include methods of treating urinary system infections, bladder cancer, incontinence, and other urinary system disorders.
-
公开(公告)号：US20240182579A1
公开(公告)日：2024-06-06
申请号：US18493568
申请日：2023-10-24
Applicant: Tayu Huaxia Biotech Medical Group Co., LTD.
Inventor： Lieping CHEN , Liqun LUO
IPC: C07K16/28 , A61K39/00 , A61P19/02 , A61P31/00 , A61P35/00 , A61P37/00 , A61P37/02 , C12N15/63 , C12N15/85
CPC classification number: C07K16/2827 , A61P19/02 , A61P31/00 , A61P35/00 , A61P37/00 , A61P37/02 , C07K16/2818 , C12N15/63 , C12N15/85 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.
-
公开(公告)号：US20240173512A1
公开(公告)日：2024-05-30
申请号：US18391989
申请日：2023-12-21
Applicant: Beyond Air LTD
Inventor： Yossef AV-GAY , David GREENBERG , Asher TAL
CPC classification number: A61M16/12 , A61K33/00 , A61K45/06 , A61P31/00 , A61B5/0833 , A61B5/14507 , A61M2202/0007 , A61M2202/0275
Abstract: The invention provides a method of treating a subject having a medical condition associated with a pathogenic microorganism, the method comprising administering to said subject a potentiating effective amount of nitric oxide; and administering to said subject a therapeutically effective amount of an antimicrobial agent, wherein said antimicrobial agent is other than said nitric oxide.
-
-
-
-
-
-
-
-
-
Search Results
328
records
(took 0.037 seconds)
